Humanized anti-mPEG/anti-HER2 BsAbs non-covalently bound to DTX-loaded LsbMDDs to enhance tumor accumulation and improve the chemotherapeutic efficacy against HER2-positive BC is schematically shown in Figure 1(A). Here, ERBB2 is linked to breast cancer.